Private equity firm ChrysCapital remains firmly in the running to buy Glenmark Pharma's stake in Glenmark Life Sciences (GLS) with rival bidder Nirma. Along with Nirma and ChrysCapital, Sekhmet Pharmaventures backed by PE firms PAG, CX Partners and Samara Capital also in the list of potential investors in the race to acquire Glenmark Pharma stake in GLS.
